Supernus, Indivior agree all-stock merger, Indivior shareholders to get $1 billion special dividend

Reuters2026/08/03 10:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused biopharma group with about USD 2.2 billion in annual revenue.
Supernus holders will receive 1.5401 Indivior shares per Supernus share; Indivior holders will get a USD 1 billion special dividend pre-close.
Dividend financing includes a USD 650 million term loan from Citibank N.A., with the balance funded from existing cash.
Post-close ownership split set at about 56.5% for Indivior holders, 43.5% for Supernus holders; combined company to be named Supernus, ticker SUPN.
Companies target USD 125 million in annual cost synergies; closing expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Supernus, Indivior agree all-stock merger, Indivior shareholders to get $1 billion special dividend

You may also like

Crypto prices